TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03659045

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: scale of pain
Description: The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scale of pain
Description: The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
Study: NCT03115866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRUVEDomics
Description: FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRUVEDomics
Description: FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRUVEDomics
Description: FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
Study: NCT04526340

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: 2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Bio-impedance measurement (BIA)
Description: for every 30 minutes for 4 hours

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bio-impedance measurement (BIA)
Description: for every 30 minutes for 4 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ingestion of testing nutrient/food capsules
Description: The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Urine sample
Description: 3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: 3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
Study: NCT03788213

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3 week RT
Description: 40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1 week RT
Description: 26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
Study: NCT03691376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Therapy
Description: Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study: NCT04438265

Intervention type: DRUG
Intervention: levobupivacaine
Description: local anesthetic

Intervention type: DEVICE
Intervention: ultrasound device
Description: scream
Study: NCT03432598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered 200 mg intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered 200 mg intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered 200 mg intravenously (IV) as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered 175 mg/m² IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered 1250 mg/m² IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered 100 mg/m2 IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered 500 mg/m² IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered 75 mg/m²/day IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered 75 mg/m²/day IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered 75 mg/m²/day IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered 75 mg/m²/day IV as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered AUC 5 as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered AUC 5 as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered AUC 5 as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered AUC 5 as specified in the treatment arm
Study: NCT03133221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zydelig
Description: Zydelig given at 150mg continuously in 28-day cycles
Study: NCT04370691

Intervention type: DEVICE
Intervention: JETi Peripheral Thrombectomy System
Description: The JETi System is is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
Study: NCT03136744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Less with MS
Description: The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
Study: NCT01478529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: iv administration
Study: NCT04418570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive remediation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attendance to an Early Intervention Service for Psychosis

Intervention type: OTHER
Group type: OTHER
Intervention: attendance to an Early Intervention Service for Psychosis
Study: NCT00568035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QR-333
Description: QR-333 or placebo will be applied three times a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QR-333
Description: QR-333 or placebo will be applied three times a day for 12 weeks
Study: NCT03755713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0892
Description: Intradermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0892
Description: Intradermal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal; normal saline solution
Study: NCT00870740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab High Yield Process)
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC injection
Study: NCT04555551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of MCARH109 T cells
Description: Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
Study: NCT04637854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operating microscope
Description: Third molar extraction using microscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical loupes
Description: Third molar extraction using loupes with co-axial illumination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Naked eyes
Description: Third molar extraction using naked eyes
Study: NCT02542111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV
Study: NCT00834145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A mechanical compression pump
Description: Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
Study: NCT00662506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging
Description: Undergo DTI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo T1 weighted DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo 18 FDG PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo PWI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18 F FDG-PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04700020

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ITT
Description: In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal. MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland. This is needed for better analysis of the pituitary gland, as the pituitary volume could be important for the hormonal abnormalities.
Study: NCT01033019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225 0.75%
Description: 0.75% cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: matching placebo cream to 0.75% LDE225 cream
Study: NCT00817843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 6 weeks of treatment with simvastatin 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 6 weeks of treatment with simvastatin 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Description: 6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Description: 6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
Study: NCT02524925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast track protocol
Description: Evaluation of postoperative stress
Study: NCT03931941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBX2660
Description: RBX2660 is a microbiota suspension administered as an enema
Study: NCT03753802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy
Description: During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Surveillance
Description: The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
Study: NCT03476486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thread carpal tunnel release
Description: Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
Study: NCT01569191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Tear Supplement
Description: artificial tear supplement (Hypromellose)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold compress
Description: Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-allergic Medication
Description: 1 drop on single occasion after exposure to grass pollen
Study: NCT03521128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiological tubal blockage
Description: In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic salpingectomy
Description: In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
Study: NCT01186289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin
Description: high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
Study: NCT02968758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison between GenePOC PCR and Reference Method
Description: Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
Study: NCT00963859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic surgery
Description: During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
Study: NCT02811068

Intervention type: OTHER
Intervention: venepuncture
Description: single venepuncture
Study: NCT01499836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PVB
Description: paravertebral block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB
Description: paravertebral block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB
Description: paravertebral block
Study: NCT00283296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor
Description: Collapsible, forward folding manual wheelchair
Study: NCT03278275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NOTA-AE105
Description: One injection of 68Ga-NORA-AE105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
Study: NCT02528994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: Participants will take dietary serine supplementation daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: Participants will take dietary serine supplementation daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: Participants will take dietary serine supplementation daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: Participants will take dietary serine supplementation daily